Peginterferon-α2b and ribavirin

References

• Alter MJ, Kruszon-Moran D, Nainan OV, etal.The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. NEJM341, 556–562 (1999).
   Google Scholar
• Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology31, 777–782 (2000).
   Google Scholar
• Seeff LB, Natural history of chronic hepatitis C. Hepatology36, S35—S46 (2002).
   Google Scholar
• Fattovich G, Giustina G, Degos F, Tremolada F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology112,463-472 (1997).
   Google Scholar
• National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002. Hepatology36, S3—S20 (2002).
   Google Scholar
• Poynard T, Leroy V, Cohard M, etal, for the Consensus Interferon Study Group. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology24, 778–789 (1996).
   Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, etal.Interferon-a2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. NEJNI339, 1485–1492 (1998).
   Google Scholar
• Poynard T, Marcellin E, Lee SS, etal, for the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus inteferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352, 1426–1432 (1998).
   Google Scholar
• Lindsay KL, Trepo C, Heintges T, etal, and the Hepatitis Interventional Therapy Group, A randomized, double-blind trial comparing pegylated interferon-a2b to interferon-a2b as initial treatment for chronic hepatitis C. Hepatology 34,395–403 (2001).
   PubMed Web of Science ®Google Scholar
• Jen JF, Glue P, Ezzet F, etal. Population pharmacokinetic analysis of pegylated interferon-a2b and interferon-a2b in patients with chronic hepatitis C. Clin. Pharrnacol. Ther. 69,407–421 (2001).
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchinson JG, Gordon SC, et al., and the International Hepatitis Interventional Therapy Group. Peginterferon-a2b plus ribavirin compared with interferon-a2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358,958–965 (2001).
   PubMed Web of Science ®Google Scholar
• ••Pivotal trial revealing the superiority ofPEG-IFN-a2, plus ribavirin in comparison with ON-a2b plus ribavirin.
   Google Scholar
• Luxon B, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin. Ther. 24(9), 1363–1383 (2002).
   PubMed Web of Science ®Google Scholar
• He X-H, Shaw P-C, Tam S-C. Reducing the immunogenicity and improving in the in vitro activity of trichosanthin by site-directed pegylation. Life Sci. 65,355–368 (1999).
   PubMed Web of Science ®Google Scholar
• Grace M, Youngster S, Giffin G, et al Structural and biological characterization of pegylated recombinant IFN a2b. J Interferon Cytokine Res. 21,1103–1115 (2001).
   PubMed Web of Science ®Google Scholar
• PEG-Intron, package insert. Schering Corporation, Kenilworth, NJ, USA (2001).
   Google Scholar
• Hadziyannis SJ, Cheinquer H, Morgan T, et al Peginterferon-a2. (40 I(D) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind multicentre study examining effect of duration of treatment and REV dose. Hepato/. 36 (Suppl 1), 3(2002).
   Google Scholar
• Di Bisceglie AM, Hoofnagle JH. Optimal therapy of Hepatitis C. Hepatology36, S121—S127 (2002).
   Google Scholar
• Copegus®, package insert. Roche Pharmaceuticals, Nutley, NJ, USA (2002).
   Google Scholar
• Rebetron®, package insert. Schering Corporation, Kenilworth, NJ, USA (2001).
   Google Scholar
• Peters M. Mechanisms of action of interferon. Semin. Liver Dis, 9,235–239 (1989).
   PubMed Web of Science ®Google Scholar
• Thomas HC, Torok ME, Forton DM, et al Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitisC.Hepatol, 31 (Suppl. 1), 152–159 (1999).
   Google Scholar
• Neumann AU, Lam NE Dahari H, et al Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-CL therapy. Sdence 282,103–107 (1998).
   Google Scholar
• Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and Their Actions. Ann. Rev Biochem. 56,727–777 (1987).
   Web of Science ®Google Scholar
• Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Grit. Rev Clin. Lab. Sci, 29,307–341 (1992).
   PubMed Web of Science ®Google Scholar
• Glue P, Fang JVVS, Rouzier-Panis R, et al. Pegylated interferon-a2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Cilia. PharmacoL Ther, 68, 556–567 (2000).
   PubMed Web of Science ®Google Scholar
• Dusheiko G, Main J, Thomas H, Reichard O, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol, 25(5), 591–598 (1996).
   PubMed Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, et al. Inteferon a2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. NEJNI339, 1493–1499 (1998).
   Google Scholar
• Lau JYN, Tam RC, Liang J, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology35 (5), 1002–1009 (2002).
   Google Scholar
• Patterson JL, Fernandez-Loisson R, Molecular mechanism of action of ribavirin. Rev Infect. Dis. 12,1139–1146 (1990).
   PubMedGoogle Scholar
• Khakoo S, Glue E Grellier L, et al . Ribavirin and interferon a2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. BE j Clin. Phannacol, 46,563–570 (1998).
   PubMed Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, et al. Monitoring of Viral Levels During Therapy of Hepatitis C Hepatology36, S141—S151 (2002).
   Google Scholar
• Lam NP, Neumann AU, Gretch DR, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon-a. Hepatology26, 226–231 (1997).
   Google Scholar
• Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon-a2a. Gastroenterology 120, 1438–1447 (2001).
   Google Scholar
• •An excellent discussion of HCV viral kinetics in response to IFN-a and PEG-IFN-a.
   Google Scholar
• Bekkering FC, Stalgis C, McHutchinson JG, et al. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology33, 419–423 (2001).
   Google Scholar
• Glue E Rouzier-Panis R, Raffanel C, et al. and The Hepatitis C Intervention Therapy Group. A dose-ranging study of pegylated interferon-a2b and ribavirin in chronic hepatitis C. Hepatology32, 647–653 (2000).
   Google Scholar
• Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology26, 780–785 (1997).
   Google Scholar
• Lindsay KL, Trepo C, Heintges T, et al. Introduction to therapy of hepatitis C. Hepatology36, S114—S120 (2002).
   Google Scholar
• Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology1,431-435 (1981).
   Google Scholar
• Poynard T, McHutchinson J, Manns M, Trepo C, et al. Impact of pegylated interferon-a2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122,1303–1313 (2002).
   PubMed Web of Science ®Google Scholar
• Trask PC, Esper E, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanism, and future directions.j Clin. Oncol. 18,2316–2326 (2000).
   Web of Science ®Google Scholar
• Zdilar D, Franco-Bronson K, Buchler N, et al Hepatitis C, interferon-CL and depression. Hepatology31, 1207–1211 (2000).
   Google Scholar
• Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al Rapid suppression of hematopoiesis by standard or pegylated interferon-a. Gastroenterology123,141-151 (2002).
   Google Scholar
• Fried MW, Side effects of therapy of hepatitis C and their management. Hepatology36, S237—S244 (2002).
   Google Scholar
• ••An excellent discussion of the side effects ofHCV antiviral therapy and side effect management.
   Google Scholar
• De Franceschi L, Fattovich G, Turrini F, Ayi K, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatits C virus infection: role of membrane oxidative damage. Hepatology31, 997–1004 (2000).
   Google Scholar
• Dieterich DT, Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect. Dis, 185 (Suppl. 2), S128—S137 (2002).
   PubMedGoogle Scholar
• McHutchison JG, Manns M, Patel K, et al for the International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in Genotype 1-infected patients with chronic hepatitis C. Gastroenterology123,1061-1069 (2002).
   Google Scholar
• •A study revealing the importance of adherence to the antiviral regimen and the resultant improvement in SVR in patients with HCV genotype 1.
   Google Scholar
• Fried MW, Shiffman ML, Reddy R, Smith C, et al. Peginterferon-a2a plus ribavirin for chronic Hepatitis C virus infection. NEJM347(13), 975–982 (2002).
   PubMedGoogle Scholar
• ••Pivotal trial revealing the superiority ofPEG-IFN-a2a plus ribavirin in comparison to IFN-a2b plus ribavirin.
   Google Scholar
• FDA Antiviral Drug Products Advisory Committee Meeting Briefing Package (2002).
   Google Scholar